1. Home
  2. PVLA vs LYTS Comparison

PVLA vs LYTS Comparison

Compare PVLA & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PVLA
  • LYTS
  • Stock Information
  • Founded
  • PVLA 2015
  • LYTS 1976
  • Country
  • PVLA United States
  • LYTS United States
  • Employees
  • PVLA N/A
  • LYTS N/A
  • Industry
  • PVLA Biotechnology: Pharmaceutical Preparations
  • LYTS Building Products
  • Sector
  • PVLA Health Care
  • LYTS Consumer Discretionary
  • Exchange
  • PVLA Nasdaq
  • LYTS Nasdaq
  • Market Cap
  • PVLA 604.2M
  • LYTS 700.9M
  • IPO Year
  • PVLA N/A
  • LYTS N/A
  • Fundamental
  • Price
  • PVLA $73.85
  • LYTS $23.76
  • Analyst Decision
  • PVLA Strong Buy
  • LYTS Strong Buy
  • Analyst Count
  • PVLA 12
  • LYTS 2
  • Target Price
  • PVLA $68.67
  • LYTS $27.50
  • AVG Volume (30 Days)
  • PVLA 199.5K
  • LYTS 135.3K
  • Earning Date
  • PVLA 11-15-2025
  • LYTS 11-06-2025
  • Dividend Yield
  • PVLA N/A
  • LYTS 0.84%
  • EPS Growth
  • PVLA N/A
  • LYTS N/A
  • EPS
  • PVLA N/A
  • LYTS 0.79
  • Revenue
  • PVLA N/A
  • LYTS $573,377,000.00
  • Revenue This Year
  • PVLA N/A
  • LYTS $5.91
  • Revenue Next Year
  • PVLA N/A
  • LYTS $8.03
  • P/E Ratio
  • PVLA N/A
  • LYTS $29.96
  • Revenue Growth
  • PVLA N/A
  • LYTS 22.09
  • 52 Week Low
  • PVLA $11.17
  • LYTS $13.77
  • 52 Week High
  • PVLA $77.77
  • LYTS $25.50
  • Technical
  • Relative Strength Index (RSI)
  • PVLA 59.32
  • LYTS 61.07
  • Support Level
  • PVLA $70.55
  • LYTS $22.22
  • Resistance Level
  • PVLA $77.77
  • LYTS $23.92
  • Average True Range (ATR)
  • PVLA 4.49
  • LYTS 0.64
  • MACD
  • PVLA -0.67
  • LYTS 0.11
  • Stochastic Oscillator
  • PVLA 66.89
  • LYTS 93.25

About PVLA Palvella Therapeutics Inc. Common Stock

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.

Share on Social Networks: